🆕💥🟢Systematic Review and Meta-Analysis
Multiplex PCR blood culture identification panels in US hospitals were associated with earlier appropriate antimicrobial therapy and shorter hospital stay, but not lower mortality #idxposts https://t.co/o9O4Y4U6QF
🔥Just published🔥
IDSA 2026 Clinical Practice Guideline Update on the Prevention of Invasive Aspergillosis in Adult Solid Organ Transplant Recipients #idxposts
https://t.co/44xeTMiLZp
¿Nuevos #antibióticos , mejores resultados? 🤔
Lamentablemente, no siempre...
The Lancet InfecDis analiza las infecciones Gram-negativas “difíciles de tratar” en hospitales de EE. UU. 🦠💊
1️⃣ El problema: las #infecciones DTR son resistentes a antibióticos de primera línea y se asocian con una mortalidad un 40% mayor. ⚠️
2️⃣ El hallazgo: aunque la disponibilidad y el uso de nuevos antibióticos aumentaron entre 2016 y 2023, la mortalidad ajustada no cambió significativamente en la mayoría de los casos. 📉↔️
3️⃣ Una barrera importante: incluso en 2023, muchos pacientes seguían recibiendo terapia inicial discordante in vitro; en el estudio, el 84% de quienes recibieron un nuevo antibiótico inicial continuaron con terapia discordante. 🚫
4️⃣ La clave: aprobar nuevos fármacos no basta. Reconocer pronto el patógeno y su perfil de resistencia puede ser crucial para elegir antes el antibiótico adecuado. ⏱️🔬
💡 Mejora necesaria: reforzar el diagnóstico microbiológico rápido, las pruebas de sensibilidad y los programas de optimización del uso de antibióticos podría ayudar a cerrar la brecha entre disponer de nuevos fármacos y usarlos a tiempo.
🔗👇🏻💊 https://t.co/FChPKH97Wk
#ResistenciaAntibiótica #AMR #AntibioticResistance #Infectología #Microbiología #SaludPública #Medicina #SciComm #Investigación @SEMicrobiologia@SEIMC_@PRANgob
In a new blog post, @PaulSaxMD writes that a year after the SNAP trial results were presented at a scientific meeting, the peer-reviewed publications confirm the practice-changing findings. Learn more: https://t.co/LXIA6f6VU8
Full SNAP trial results published in NEJM: https://t.co/5Z39siPUhS
The field of antimicrobial therapy is undergoing a decisive recalibration: in bacterial infections, including endocarditis and bone and joint infections, recent trials have legitimized early switch to oral therapy, challenging the long-held primacy of intravenous treatment.
This paradigm shift, however, remains conspicuously underdeveloped in invasive fungal infections. @BradSpellberg #idxposts
The field of antifungal therapy stands at an inflection point. For candidemia, three ongoing randomised trials are poised to generate the first prospective evidence challenging the 14-day treatment dogma. #idxposts
In the SNAP trial, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality in patients with methicillin-susceptible Staphylococcus aureus bacteremia and had fewer nephrotoxic effects. Read the full trial results and Research Summary: https://t.co/5Z39siPUhS
Time to re-evaluate the 14-day rule?
🆕💥🔴Multicentre cohort study
Short-course antifungal therapy was not associated with increased mortality or recurrence compared with long-course therapy among patients with uncomplicated candidaemia who achieved adequate source control and microbiological clearance. #idxposts https://t.co/Tz1tQDUUnd
No new safety findings were observed for olorofim; the rate of drug-related treatment-emergent adverse events was 35.8% for olorofim and 63.9% for AmBisome® followed by standard of care, with the difference mainly driven by the higher rate of renal events in the AmBisome arm.
Great news!
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis whose infection was either refractory to or unsuitable for azole therapy
The study achieved the primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% and for AmBisome® followed by standard of care of 24.3%
https://t.co/FWXklSN2Ma